FRONTIER CAPITAL MANAGEMENT CO LLC

Position in APGE — Apogee Therapeutics, Inc.

CIK 351173 Boston, MA

Position in APGE

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$40,315,277

-$49,282,257 QoQ

Shares Held

303,739

-71.5% QoQ

Ownership

0.401%

of shares outstanding

% of Portfolio

0.38%

of 13F equity value

Holder Rank

#46

of 285 holders

Holding Since

Mar 2024

9 quarters on record

Voting authority Sole 35% Shared 0% None 65%

Healthcare · as of Jun 30, 2026

FRONTIER CAPITAL MANAGEMENT CO LLC holds $975,847,387 across 22 Biotechnology names. APGE ranks #11 (4.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	BBIO	BridgeBio Pharma, Inc.	1,373,057	$102,265,285
2	RARE	Ultragenyx Pharmaceutical Inc.	2,847,936	$95,092,583
3	KYMR	Kymera Therapeutics, Inc.	740,866	$84,955,104
4	INSM	INSMED Inc	795,242	$84,788,702
5	PVLA	Palvella Therapeutics, Inc.	478,833	$73,175,259
6	JAZZ	Jazz Pharmaceuticals plc	277,279	$66,815,920
7	AXSM	Axsome Therapeutics, Inc.	254,280	$62,240,115
8	TRVI	Trevi Therapeutics, Inc.	3,070,740	$57,269,301

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$40,315,277	303,739	-71.5%	Shares	Sole	2026-08-14
2026-03-31	$89,597,534	1,064,483	+121.6%	Shares	Sole	2026-05-15
2025-12-31	$36,264,592	480,453	+28.3%	Shares	Sole	2026-02-17
2025-09-30	$14,875,190	374,407	+21.1%	Shares	Sole	2025-11-14
2025-06-30	$13,422,736	309,066	+184.0%	Shares	Sole	2025-08-14
2025-03-31	$4,065,403	108,817	-37.0%	Shares	Sole	2025-05-15
2024-12-31	$7,823,808	172,711	-44.5%	Shares	Sole	2025-02-14
2024-09-30	$18,286,701	311,316	+307.1%	Shares	Sole	2024-11-14
2024-03-31	$5,082,162	76,481	—	Shares	Sole	2024-05-15
No filing history on record for this holder in this stock.